RxDoctor Payments Data

Sona Patel, MD

Internal Medicine · Burlington, NCNPI 1770554834

Payments from drug & device makers

$1,444in general payments, 2019–2025

Across 79 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$302
  • Johnson & Johnson$188
  • Otsuka America Pharmaceutical, Inc.$180
  • AstraZeneca$129
  • BETA Bionics, Inc.$101
  • Merck$99
  • plus $445 from 12 others

What the payments were for

  • Food & beverage$1,444100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,444 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$36,420
Medicare patients
163
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$17,834
JardianceEmpagliflozin12$6,293
Quetiapine Fumarate27$1,528
Lurasidone Hcl11$1,215
Omega-3 Acid Ethyl Esters12$1,094
Pantoprazole Sodium39$481
Atorvastatin Calcium30$423
Tamsulosin Hcl22$408
Omeprazole16$312
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$301
Lisinopril21$251
ClopidogrelClopidogrel Bisulfate24$204
Midodrine Hcl11$200
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$178
Nitroglycerin20$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$302$17,83431 claims
Boehringer IngelheimJardiance$18$6,29312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Burlington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →